By Fineline Cube Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990), a China-based biopharmaceutical company, announced it has received a payment of RMB 602,509,600.00 (USD 89 million) from Medilink Therapeutics representing the share of revenue from the out-licensing of YL201. This brings the total settlement-related payments received by Kelun-Biotech from Medilink in 2026 to RMB 702,721,325.78 (USD 104 million).
Settlement Details
| Item | Detail |
|---|---|
| Company | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) |
| Counterparty | Medilink Therapeutics |
| Latest Payment | RMB 602,509,600.00 (USD 89 million) |
| Total 2026 Payments | RMB 702,721,325.78 (USD 104 million) |
| Settlement Agreement | December 2025 |
| Dispute Origin | Criminal complaint filed in 2024; civil litigation initiated in 2025 |
| Allegations | Misappropriation of trade secrets and harm to company interests |
ADC Pipeline Assets Covered Under Settlement
| Asset | Target | Therapeutic Focus |
|---|---|---|
| YL201 | B7H3 | Antibody-drug conjugate (ADC) |
| YL202 | HER3 | Antibody-drug conjugate (ADC) |
| YL211 | cMet | Antibody-drug conjugate (ADC) |
| YL212 | DLL3 | Antibody-drug conjugate (ADC) |
| YL221 | EGFR | Antibody-drug conjugate (ADC) |
| YL222 | PD-L1 | Antibody-drug conjugate (ADC) |
The settlement agreement entitles Kelun-Biotech to receive a certain percentage of proceeds generated from both past out-licensing transactions and future sales of these six ADC pipeline assets.
Legal Dispute Timeline
| Date | Action |
|---|---|
| 2024 | Kelun-Biotech filed criminal complaint against Medilink Therapeutics |
| 2025 | Kelun-Biotech initiated civil litigation against Medilink |
| December 2025 | Parties entered into comprehensive settlement agreement |
| 2026 (YTD) | Kelun-Biotech received USD 104 million in settlement payments |
Strategic & Financial Implications
- Revenue Recognition: The settlement payments represent significant non-operating income that will positively impact Kelun-Biotech’s 2026 financial performance
- Intellectual Property Protection: Successful resolution validates Kelun-Biotech’s IP rights over its ADC platform technology and specific asset developments
- Pipeline Monetization: Despite the dispute, the underlying ADC assets have demonstrated commercial value through out-licensing transactions
- Corporate Governance: Demonstrates management’s commitment to protecting shareholder interests and defending company assets
Market Context & Industry Significance
- ADC Market Growth: The global antibody-drug conjugate market is projected to exceed USD 20 billion by 2030, driven by advances in linker technology and target identification
- Chinese Biotech Innovation: Kelun-Biotech’s multi-target ADC pipeline reflects the growing sophistication of Chinese biopharmaceutical R&D capabilities
- IP Enforcement Precedent: The successful settlement may encourage other Chinese biotech companies to more aggressively protect their intellectual property rights internationally
- Partnership Risks: Highlights the importance of robust contractual protections in biotech collaborations and out-licensing arrangements
The resolution of this high-profile dispute strengthens Kelun-Biotech’s financial position while affirming the commercial value of its ADC platform and pipeline assets.
Forward-Looking Statements
This brief contains forward-looking statements regarding settlement proceeds, future payments, and business implications. Actual results may differ due to risks including payment timing, contractual interpretations, and market conditions.-Fineline Info & Tech